Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.51 |
| ▸ | GABRD | O14764 | 4/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.51 |
| ▸ | GABRE | P78334 | 4/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592241 | 1.00 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL23218349 | 0.80 | PIM1 (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29853136 | 0.72 | KCNH2 (0.47) | KMT2APIM1LMNASMN1; SMN2KCNH2 | |
| SCHEMBL23218435 | 0.72 | KCNH2 (0.47) | KMT2APIM1LMNASMN1; SMN2KCNH2 | |
| SCHEMBL2401078 | 0.72 | ALOX5 (0.65) | KMT2AKDM4E | |
| SCHEMBL2404910 | 0.72 | ATM (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29852823 | 0.72 | ATM (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14764491 | 0.72 | CYP3A4 (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28159082 | 0.71 | MEN1 (0.48) | KMT2AANO1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL23218086 | 0.70 | PIM1 (0.45) | KMT2APIM1LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | GABRP 110/4885GABRD 1347/4885GABRA1 649/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | GABRP 2631/4885GABRD 2643/4885GABRA1 3792/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | GABRP 3568/4885GABRD 3702/4885GABRA1 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.